112 results about "Vesicular stomatitis virus VSV" patented technology

A process is described for purifying vesicular stomatitis virus (VSV) from cell culture fluid of a mammalian cell culture infected with VSV, the process comprising: clarifying the cell culture fluid by low-speed centrifugation and recovering the VSV in the supernatant; filtering the supernatant through a 0.2 to 0.45 μm filter and recovering the VSV in the filtered solution; loading the VSV filtered solution onto a anion exchange membrane adsorber equilibrated with a first pH buffered salt solution, eluting the VSV from the anion exchange membrane adsorber with a second pH buffered salt solution and recovering the eluted VSV fractions; purifying the recovered VSV by tangential flow filtration (TFF) using a TFF membrane having a molecular weight cutoff between 300 kDa and 1,000 kDa and recovering the VSV in the retentate, and filtering the VSV retentate through a 0.2 to 0.22 μm filter and recovering the VSV in the filtered solution.

Immunization platforms, immunization regimes and medicaments useful for inducing an immune response in a mammal and preventing or treating a pathogenic infection in a mammal, wherein said immunization platforms and medicaments comprise a recombinant vesicular stomatitis virus (VSV) of one serotype and a rVSV of another serotype and are used in a prime-boost immunization regime. In aspects of the invention one VSV serotype is Indiana and the other VSV serotype is New Jersey.

The present invention provides an antimicrobial composition, which comprises a lauroyl lauroyl arginate (LAE) ion pair derivative, and the antimicrobial composition is an antiviral agent against an enveloped virus, wherein the enveloped virus is selected from vesicular stomatitis virus of the herpes virus, or the Newcastle disease virus selected from the paramyxovirus. The antiviral agent is the anti-infective agent comprising a condensate derived from fatty acid and esterified binary amino acid, and is capable of acting on Newcastle disease virus and vesicular stomatitis virus in-vitro, and reducing the infection of Newcastle disease virus and vesicular stomatitis virus to cells. The antiviral agent is added to the cultured Newcastle disease virus (NDV) and vesicular stomatitis virus (VSV), or the antiviral agent is added at different times before the virus is infected and after the infection, the infected cells are detected, and the number of viruses is found to be significantly reduced. The antiviral agent can effectively inhibit or kill the virus and can be used to prevent or reduce the ability of the virus to infect cells. The present invention also provides a method of preparing the antimicrobial composition, which has the characteristics of better virucidal effect and lower dosage than that of the original antimicrobial composition containing a LAE compound.